Inmune Z Score

INMB
 Stock
  

USD 6.72  0.18  2.61%   

Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Please see Inmune Bio Piotroski F Score and Inmune Bio Valuation analysis.
  
Inmune Bio Invested Capital is projected to increase significantly based on the last few years of reporting. The past year's Invested Capital was at 19.5 Million. The current year Invested Capital Average is expected to grow to about 14.6 M, whereas Return on Invested Capital is forecasted to decline to (2.42) . Inmune Bio Operating Expenses is projected to increase significantly based on the last few years of reporting. The past year's Operating Expenses was at 29.33 Million. The current year Research and Development Expense is expected to grow to about 22.2 M, whereas Consolidated Income is forecasted to decline to (31.1 M).

Inmune Z Score Analysis

Inmune Bio's Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
 2010 2021 2022 (projected)
Revenues USD11 K181 K150.84 K
Revenues10.92 K181 K195.29 K
Z Score 
 = 
Sum Of  
 
5 Factors 
More About Z Score | All Equity Analysis

Current Inmune Bio Z Score

    
  3.4  
Most of Inmune Bio's fundamental indicators, such as Z Score, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Inmune Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
First Factor
 = 
1.2 * (
Working Capital
/
Total Assets )
Second Factor
 = 
1.4 * (
Retained Earnings
/
Total Assets )
Thrid Factor
 = 
3.3 * (
EBITAD
/
Total Assets )
Fouth Factor
 = 
0.6 * (
Market Value of Equity
/
Total Liabilities )
Fifth Factor
 = 
0.99 * (
Revenue
/
Total Assets )

Inmune Z Score Driver Correlations

Understanding the fundamental principles of building solid financial models for Inmune Bio is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Z Score. Since Inmune Bio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Inmune Bio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Inmune Bio's interrelated accounts and indicators.
To calculate Z-Score one would need to know current working capital of the company, its total assets, and liabilities, amount of latest retained earnings as well as earnings before interest and tax. Z-Score can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area' with scores of less than 1, indicating the high probability of distress. Z Score is used widely by financial auditors, accountants, money managers, loan processers, wealth advisers, as well as day traders. In the last 25 years, many financial models that utilize z score has been proved to be successful as a predictor of corporate bankruptcy.
Compare to competition

According to the company's disclosures, Inmune Bio has a Z Score of 3.4. This is 49.63% lower than that of the Healthcare sector and about the same as Biotechnology (which currently averages 3.34) industry. The z score for all United States stocks is 61.01% higher than that of the company.

Inmune Z Score Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Inmune Bio's direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Inmune Bio could also be used in its relative valuation, which is a method of valuing Inmune Bio by comparing valuation metrics of similar companies.
Inmune Bio is currently under evaluation in z score category among related companies.

Inmune Bio Current Valuation Drivers

We derive many important indicators used in calculating different scores of Inmune Bio from analyzing Inmune Bio's financial statements. These drivers represent accounts that assess Inmune Bio's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Inmune Bio's important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(831.49 K)(12.44 M)(7.76 M)(12.1 M)(30.34 M)(31.14 M)
Earnings Before Interest Taxes and Depreciation Amortization USD(831.49 K)(12.44 M)(7.68 M)(12.1 M)(30.34 M)(31.14 M)
Earnings before Tax(831.49 K)(12.44 M)(7.68 M)(12.1 M)(30.34 M)(31.14 M)
Free Cash Flow(761.83 K)(2.06 M)(5.38 M)(8.94 M)(28.5 M)(29.25 M)
Invested Capital219.04 K(160.63 K)428.87 K559 K19.5 M21.04 M
Tangible Asset Value1.9 M849.34 K7.96 M24.14 M83.43 M90.02 M
Working Capital1.59 M25.58 K7.06 M22.21 M78.25 M84.42 M

Inmune Bio Institutional Holders

Institutional Holdings refers to the ownership stake in Inmune Bio that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Inmune Bio's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Inmune Bio's value.
Security TypeSharesValue
Yorkbridge Wealth Partners LlcCommon Shares10.4 K64 K
Yorkbridge Wealth Partners LlcCommon Shares10.4 K92 K
Yorkbridge Wealth Partners LlcCommon Shares10.4 K87 K
Yorkbridge Wealth Partners LlcCommon Shares10.4 K106 K
Yorkbridge Wealth Partners LlcCommon Shares10.4 K201 K
Yorkbridge Wealth Partners LlcCommon Shares10.4 K182 K
Westside Investment Management IncCommon Shares30.1 K266

Inmune Fundamentals

About Inmune Bio Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Inmune Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Inmune Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Inmune Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patients innate immune system to treat disease. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida. Inmune Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Inmune Bio without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Equity Valuation Now

   

Equity Valuation

Check real value of public entities based on technical and fundamental data
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Inmune Bio using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Inmune Bio Piotroski F Score and Inmune Bio Valuation analysis. You can also try Analyst Recommendations module to analyst recommendations and target price estimates broken down by several categories.

Complementary Tools for analysis

When running Inmune Bio price analysis, check to measure Inmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inmune Bio is operating at the current time. Most of Inmune Bio's value examination focuses on studying past and present price action to predict the probability of Inmune Bio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Inmune Bio's price. Additionally, you may evaluate how the addition of Inmune Bio to your portfolios can decrease your overall portfolio volatility.
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Is Inmune Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inmune Bio. If investors know Inmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
123.8 M
Quarterly Revenue Growth YOY
6.0
Return On Assets
(0.19) 
Return On Equity
(0.41) 
The market value of Inmune Bio is measured differently than its book value, which is the value of Inmune that is recorded on the company's balance sheet. Investors also form their own opinion of Inmune Bio's value that differs from its market value or its book value, called intrinsic value, which is Inmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inmune Bio's market value can be influenced by many factors that don't directly affect Inmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine Inmune Bio value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.